Loading
HKSEHealthcareMedical - Devices
Latest quote
HK$21.16
−HK$0.84 · -3.82%
Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.
Latest quote
HK$21.16
−HK$0.84 · -3.82%
Regular session · HKT · Market data may be delayed.
Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.
Day range
Current HK$21.16
52-week range
Current HK$21.16
Regular session · HKT · Market data may be delayed.
Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.
Day range
Current HK$21.16
52-week range
Current HK$21.16
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.06B CNY | 782.48M CNY | 527.75M CNY | 334.09M CNY | 177.91M CNY |
| Cost of goods sold | 294.57M CNY | 222.58M CNY | 142.77M CNY | 81.42M CNY | 46.03M CNY |
| Gross profit | 762.92M CNY | 559.9M CNY | 384.99M CNY | 252.67M CNY | 131.88M CNY |
| Research and development | 246.78M CNY | 233.23M CNY | 261.01M CNY | 233.46M CNY | 168.1M CNY |
| Selling, general, and administrative | 315.87M CNY | 265.76M CNY | 277.92M CNY | 249.47M CNY | 195.87M CNY |
| Operating expenses | 562.65M CNY | 499.02M CNY | 541.51M CNY | 474.86M CNY | 349.94M CNY |
| Interest income | 54.64M CNY | 67.35M CNY | 79.04M CNY | 95.57M CNY | 13.09M CNY |
| Interest expense | 996.52K CNY | 2.18M CNY | 1.25M CNY | 722K CNY | 307K CNY |
| Depreciation and amortization | 33.1M CNY | 29.11M CNY | 35.88M CNY | 26.27M CNY | 9.68M CNY |
| Operating income | 196.64M CNY | 60.92M CNY | −156.52M CNY | −208.4M CNY | −212.48M CNY |
| Net income | 244.37M CNY | 100.26M CNY | −78.73M CNY | −113.56M CNY | −199.69M CNY |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 27, 2026 | HK$0.2516Annual | May 28, 2026 | Jun 18, 2026 |
Dividend | Jun 4, 2025 | HK$0.109Special | Jun 5, 2025 | Jun 27, 2025 |
Ex-dividend May 27, 2026
HK$0.2516
Annual
Record May 28, 2026 · Payment Jun 18, 2026
Ex-dividend Jun 4, 2025
HK$0.109
Special
Record Jun 5, 2025 · Payment Jun 27, 2025
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
